Research
Hormonal
Tirzepatide demonstrates potential for cardiovascular protection, including reduced risk of major adverse cardiovascular events (MACE-4) and improved lipid profiles, in patients with Type 2 Diabetes.
Beyond lowering blood sugar, Tirzepatide may improve heart health by lowering bad cholesterol and triglycerides and reducing the risk of heart attacks and strokes. This is particularly important for diabetic patients with existing heart risks.
ModerateSupportsMEDIUM confidence
tirzepatide had a lower risk of MACE-4 (cardiovascular death, myocardial infarction, stroke, and unstable angina)... observed a time-dependent dose-dependent reduction in levels of triglycerides, apoB, apoC-III
Why this rating
Based on post-hoc analyses and meta-analyses of SURPASS trials; definitive CVOT results (SURPASS-CVOT) were ongoing at time of publication.
Source
Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
Zijun Ma et al. · Journal of Diabetes Research · 2023
DOI 10.1155/2023/5891532
narrative_reviewCited 19×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior glycemic control and greater weight loss compared to GLP-1 receptor agonists (semaglutide, dulaglutide) and insulin analogs (degludec, glargine) in patients with type 2 diabetes.Good
- Tirzepatide shows promise for treating Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) by reducing liver fat content and improving liver enzymes, likely through indirect weight loss and metabolic effects.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →